ChemicalBook
Chinese Japanese Germany

Moxifloxacin hydrochloride

Indications and Usage Mechanisms of Action Pharmacokinetics Adverse Effects Warnings and Precautions Adverse reactions Precautions
Moxifloxacin hydrochloride
Moxifloxacin hydrochloride
CAS No.
186826-86-8
Chemical Name:
Moxifloxacin hydrochloride
Synonyms
ACTIRA;Avelox;AVALOX;Actura;PROFLOX;BAY-12-8039;BAY12-8039 HCl;MOXIFLOXACIN HCL;Moxiflaxacin HCL;MoxifloxacineHCl
CBNumber:
CB3191433
Molecular Formula:
C21H25ClFN3O4
Formula Weight:
437.8923032
MOL File:
186826-86-8.mol

Moxifloxacin hydrochloride Properties

Melting point:
Slightly yellow to yellow crystalline powder, mp 324-325°
alpha 
25D -256° (c = 0.5 in water)
Boiling point:
636℃
RTECS 
VB1983750
Flash point:
>110°(230°F)
storage temp. 
2-8°C
solubility 
H2O: soluble5mg/mL, clear (warmed)
form 
powder
color 
white to beige
Water Solubility 
Sparingly soluble in water. Soluble in DMSO
BRN 
8377447
InChIKey
IDIIJJHBXUESQI-DFIJPDEKSA-N
CAS DataBase Reference
186826-86-8(CAS DataBase Reference)

SAFETY

WGK Germany  2
HazardClass  IRRITANT

Moxifloxacin hydrochloride price More Price(12)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich PHR1542 Moxifloxacin hydrochloride Pharmaceutical Secondary Standard; Certified Reference Material 186826-86-8 1g $72.1 2018-11-20 Buy
Sigma-Aldrich 1448606 Moxifloxacin hydrochloride United States Pharmacopeia (USP) Reference Standard 186826-86-8 200mg $923 2018-11-13 Buy
Alfa Aesar J66626 Moxifloxacin hydrochloride, 97% 186826-86-8 500mg $470 2018-11-13 Buy
Alfa Aesar J66626 Moxifloxacin hydrochloride, 97% 186826-86-8 100mg $118 2018-11-13 Buy
Cayman Chemical 14830 Moxifloxacin (hydrochloride) ≥95% 186826-86-8 50mg $75 2018-11-13 Buy

Moxifloxacin hydrochloride Chemical Properties,Uses,Production

Indications and Usage

Moxifloxacin Hydrochloride is a fluoroquinolone antibiotic developed by Bayer Pharmaceuticals (Germany.) It can be used to treat community-acquired pneumonia caused by Staphylococcus aureus, baccilus, pneumococcus, mucositis Moraxella, and Klebsiella pneumoniae, acute chronic bronchitis attacks, and acute sinusitis. For the treatment of adult bacterial lung infections, paranasal sinus, skin, and abdominal cavity. Also used to treat community-acquired pneumonia, chronic bronchitis, urogenital infection, and acute sinusitis.

Mechanisms of Action

Its active mechanisms and in vitro antibacterial spectrums are similar to those of other fluoroquinolones, but its profile towards gram-positive and anaerobic bacteria is similar to that of trovafloxacin, better than some older drugs. Compared with other fluoroquinolones, few gram-positive bacteria are resistant to Moxifloxacin Hydrochloride, or the spread of resistance is very slow. Gram-negative and enterococci strains with cross resistance to other fluoroquinolones have been found. It is effective at least against Staphylococcus aureus strains grlA, grlB, gyrA and gyrBcan, and 0.5-2 mg/L can inhibit Ciprofloxacin resistant Staphylococcus aureus, from large MIC to small Ciprofloxacin, Ofloxacin, Levofloxacin, Sparfloxacin, and Moxifloxacin.

Pharmacokinetics

After 45 healthy volunteers were orally administered single doses of 50-800 mg, their peak plasma concentration and area under the curve (AUC) increased linearly with dosage. Recommended oral dose is 400 mg, average Cmax is 2.5mg/L, peak time (tmax) is 1.5 hours, and AUC is 26.9 mg•h/L. For healthy volunteers who took 400 mg per day orally for 10 days, Cmax was 4.52 mg/L, 1.59 accumulated over 10 days. Oral bioavailability is 89%, apparent distribution volume 3.55 L/kg, plasma protein binding rate 48%. For 400 mg intravenously, Cmaxis 3.62 mg/L. AUC 34.6 mg•h/L. 24 hours after 13 healthy volunteers were given a single oral dose or intravenous injection of 400 mg, skin blister fluid concentration was twice that of serum, suggesting easier penetration of interstitial tissue. One hour after 18 patients ingested a single oral dose of 400 mg before undergoing bronchoscopy, bronchial epithelial cell fluid and bronchial biopsy tissue concentrations were 24.4 and 5.5 mg / L respectively, greater than the plasma concentration after 12 hours. An extremely high concentration (113.6 mg/L) was reached in macrophages. After 34 patients with chronic sinusitis received 5 oral doses of 400 mg, concentration in maxillary sinus mucosa exceeded blood plasma concentration. Three hours after the last dose, blood concentration peaked at 7.47 mg/kg; after 36 hours it was 1.25 mg/kg,suggesting a post-dosage effect.
After healthy volunteers received an oral dose of 400 mg, total clearance rate and renal clearance rates were 14.9 and 3.03 L per hour respectively. The drug apparently does not undergo P450 metabolism. Metabolized in vitro into N-sulfate and acyl glucuronide, metabolites inactive. After healthy volunteers took 400 mg/d orally, the average elimination half-life (t1/2β) during the first day was 9.3 hours, 11.95 hours over 10 days. Another study showed that the average t1/2β is about 10-16 hours. After a single oral dose or intravenous infusion of 400 mg, the urine reabsorption rates were 19%-20% and 22% respectively.

Adverse Effects

The adverse effects of this product are mostly mild and transient, and 3.8% of patients discontinued treatment as a result of adverse effects. The most common effects were nausea (7.2%) and diarrhea (5.7%). The incidence of dizziness was 2.8%. Healthy volunteers experienced no changes in vital signs, hematology, blood biochemistry, and ECG. Studies show that it is different from lomefloxacin and did not show any phototoxicity.

Warnings and Precautions

Similar to other fluoroquinones, bioavailability of 400 mg of Moxifloxacin Hydrochloride declined significantly after combination with antacids. AUC and cmax decreased 45% and 40% compared with when used alone, but Moxifloxacin Hydrochloride absorption was not significantly affected when taken 2 hours before or 4 hours after taking antacids. When taken with iron, absorption decreased significantly, with AUC and cmax was 39% and 59% lower, respectively. No interaction with theophylline, probenecid, ranitidine, or warfarine.

Adverse reactions

Side effects of this product are mostly mild and transient , 3.8% of the patient discontinued treatment due to adverse events . The most common adverse reactions are nausea (7.2%) and diarrhea (5.7%). Dizziness is 2.8%. In healthy volunteers, no changes in vital signs, hematology, blood biochemistry and electrocardiogram.
Studies have shown that the product is different from lomefloxacin , no drug-induced light toxicity.

Precautions

Similar to other fluoroquinolones , the product (400mg) in combination with antacids, bioavailability will fall significantly, AUC and cmax fall down 45% and 40% respectively when compared with alone, but using the moxifloxacin hydrochloride 2h before taking antacids or using antacids 4h after using this service, the absorption of the drug has no effect. If the product in combination with iron ,absorption rate decreases, AUC and cmax are reduced by 39% and 59%. The product has no interaction with theophylline, probenecid, ranitidine and warfarin .

Chemical Properties

Light yellow to yellow crystalline powder

Uses

acetylcholinesterase inhibitor (reversible), cognitive enhancer

Uses

An antibacterial agent that inhibits the activities of Topo II (DNA gyrase) and topoisomerase IV

Definition

ChEBI: A hydrochloride comprising equimolar amounts of moxifloxacin and hydrogen chloride.

brand name

Avelox (Bayer); Vigamox (Alcon.

Moxifloxacin hydrochloride Preparation Products And Raw materials

Raw materials

Preparation Products


Moxifloxacin hydrochloride Suppliers

Global( 285)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 sales@capotchem.com China 19953 60
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3217 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 22046 58
Nanjing Gold Pharmaceutical Technology Co. Ltd.
025-84209270 15906146951
025-84209270 wgp@nanjing-pharmaceutical.com CHINA 117 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20786 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32651 55
PI & PI BIOTECH INC.
020-81716320
020-81716319 Sales@pipitech.com CHINA 2548 55
Hefei TNJ Chemical Industry Co.,Ltd.
86-0551-65418684 18949823763
86-0551-65418684 info@tnjchem.com China 1659 55
QUALITY CONTROL CHEMICALS INC.
13606120588
orders@qcchemical.com CHINA 8430 58
Hubei Jusheng Technology Co.,Ltd.
86-155-27864001
peter@hubeijusheng.com CHINA 18004 58

View Lastest Price from Moxifloxacin hydrochloride manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-08-20 Moxifloxacin hydrochloride
186826-86-8
US $1.00 / KG 1KG 99% Customnized career henan chemical co

186826-86-8(Moxifloxacin hydrochloride)Related Search:


  • 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO- 8-METHOXY-7- [(4AS,7AS)-OCTAHYDRO-6H-PYRROLO[3,4-B]PYRIDIN-6-YL]-4-OXO-3-QUINOLINECARBOXYLIC ACID HYDROCHLORIDE
  • 1-CYCLOPROPYL-7-[(S,S)-2,8-DIAZA-BICYCLO[4.3.0]NON-8-YL]-6-FLUORO-8-METHOXY-1,4-DIHYDRO-4-OXO-3-QUINOLINE CARBOXYLIC ACID HYDROCHLORIDE
  • ACTIRA
  • PROFLOX
  • MOXIFLOXACIN HCL
  • MOXIFLOXACIN HYDROCHLORIDE
  • MoxifloxacineHCl
  • Moxifloxacinehydrochloride
  • 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7- [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-,monohydrochloride
  • Moxiflaxacin HCL
  • Moxifloxacin Hydrochloride (200 mg)
  • 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, Monohydrochloride, (4aS-cis)-
  • Moxifloxacin Hydrochlorideand
  • 1-Cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydro-1H-pyrrolo[3,4-b]pyridin-6(2H)-yl)-8-Methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
  • Avelox
  • 1-Cyclopropyl-6-fluoro-8-Methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
  • AVALOX
  • BAY-12-8039
  • (1's,6's)-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
  • 1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
  • BAY12-8039 HCl
  • Moxifloxacin hydrochloride, >=99%
  • 4-dihydroquinoline-3-carboxylic acid hydrochloride
  • Moxifloxacin Hydrochloride 1
  • Moxifloxacin Hydrochloride Tablets
  • Moxifloxacin hydrochlorideUSP, 98.0-102.0% (HPLC)
  • Actura
  • Moxifloxacin hydrochloride Solution, 1000ppm
  • 86826-86-8
  • -
  • 186826-86-8
  • 196826-86-8
  • C21H24FN3O4HCl
  • C21H24FN3O4ClH
  • C22H25FN3O4
  • C21H25FN3O4Cl
  • Active Pharmaceutical Ingredients
  • Moxifloxacin
  • API
  • ARICEPT
  • Moxifloxacin and intermediates
  • Moxifloxacin HCl (Monohydrate)
  • (1's,6's)-1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
  • Moxifloxacin HCl USP
Copyright 2017 © ChemicalBook. All rights reserved